# Stuart Neil

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 84 papers | 7,493 citations | 40 h-index | 86 g-index |
| 87 ext. papers | 9,030 ext. citations | 12.2 avg, IF | 6.09 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 84 | Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. *Nature*, **2008**, 451, 425-30 | 50.4 | 1369 |
| 83 | Transcytosis and surface presentation of IL-8 by venular endothelial cells. *Cell*, **1997**, 91, 385-95 | 56.2 | 671 |
| 82 | Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. *Nature Microbiology*, **2020**, 5, 1598-1607 | 26.6 | 667 |
| 81 | Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. *Journal of Virology*, **2009**, 83, 1837-44 | 6.6 | 319 |
| 80 | Plasma membrane is the site of productive HIV-1 particle assembly. *PLoS Biology*, **2006**, 4, e435 | 9.7 | 269 |
| 79 | Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. *PLoS Pathogens*, **2009**, 5, e1000300 | 7.6 | 246 |
| 78 | Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. *Journal of Virology*, **2009**, 83, 11966-78 | 6.6 | 234 |
| 77 | Innate sensing of HIV-1 assembly by Tetherin induces NFB-dependent proinflammatory responses. *Cell Host and Microbe*, **2012**, 12, 633-44 | 23.4 | 218 |
| 76 | HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. *PLoS Pathogens*, **2006**, 2, e39 | 7.6 | 211 |
| 75 | An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. *Cell Host and Microbe*, **2007**, 2, 193-203 | 23.4 | 208 |
| 74 | Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. *Nature Medicine*, **2020**, 26, 1701-1707 | 50.5 | 170 |
| 73 | Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells. *Journal of Virology*, **2010**, 84, 12185-99 | 6.6 | 145 |
| 72 | Host factors involved in retroviral budding and release. *Nature Reviews Microbiology*, **2011**, 9, 519-31 | 22.2 | 145 |
| 71 | Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility. *Cell Host and Microbe*, **2008**, 4, 52-62 | 23.4 | 143 |
| 70 | Cell Surface Proteomic Map of HIV Infection Reveals Antagonism of Amino Acid Metabolism by Vpu and Nef. *Cell Host and Microbe*, **2015**, 18, 409-23 | 23.4 | 118 |
| 69 | Postentry restriction to human immunodeficiency virus-based vector transduction in human monocytes. *Journal of Virology*, **2001**, 75, 5448-56 | 6.6 | 115 |
| 68 | Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction. *Cell Host and Microbe*, **2016**, 20, 429-442 | 23.4 | 115 |

| | | | |
|---|---|---|---|
| 67 | The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin. *PLoS Pathogens*, **2010**, 6, e1000843 | 7.6 | 113 |
| 66 | Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein. *Journal of Virology*, **2010**, 84, 12958-70 | 6.6 | 107 |
| 65 | Human immunodeficiency virus, restriction factors, and interferon. *Journal of Interferon and Cytokine Research*, **2009**, 29, 569-80 | 3.5 | 106 |
| 64 | The origins of SARS-CoV-2: A critical review. *Cell*, **2021**, 184, 4848-4856 | 56.2 | 103 |
| 63 | HIV-1 Vpu Mediates HLA-C Downregulation. *Cell Host and Microbe*, **2016**, 19, 686-95 | 23.4 | 81 |
| 62 | Susceptibility of xenotropic murine leukemia virus-related virus (XMRV) to retroviral restriction factors. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 5166-71 | 11.5 | 80 |
| 61 | A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction. *PLoS Pathogens*, **2012**, 8, e1002609 | 7.6 | 79 |
| 60 | The UBAP1 subunit of ESCRT-I interacts with ubiquitin via a SOUBA domain. *Structure*, **2012**, 20, 414-28 | 5.2 | 76 |
| 59 | The antiviral activities of tetherin. *Current Topics in Microbiology and Immunology*, **2013**, 371, 67-104 | 3.3 | 74 |
| 58 | Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. *PLoS Pathogens*, **2020**, 16, e1008817 | 7.6 | 72 |
| 57 | KHNYN is essential for the zinc finger antiviral protein (ZAP) to restrict HIV-1 containing clustered CpG dinucleotides. *ELife*, **2019**, 8, | 8.9 | 66 |
| 56 | The Polybasic Cleavage Site in SARS-CoV-2 Spike Modulates Viral Sensitivity to Type I Interferon and IFITM2. *Journal of Virology*, **2021**, 95, | 6.6 | 63 |
| 55 | Antiviral inhibition of enveloped virus release by tetherin/BST-2: action and counteraction. *Viruses*, **2011**, 3, 520-40 | 6.2 | 62 |
| 54 | The promiscuous CC chemokine receptor D6 is a functional coreceptor for primary isolates of human immunodeficiency virus type 1 (HIV-1) and HIV-2 on astrocytes. *Journal of Virology*, **2005**, 79, 9618-24 | 6.6 | 61 |
| 53 | SARS-CoV-2 Is Restricted by Zinc Finger Antiviral Protein despite Preadaptation to the Low-CpG Environment in Humans. *MBio*, **2020**, 11, | 7.8 | 60 |
| 52 | Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. *Immunity*, **2021**, 54, 1276-1289.e6 | 32.3 | 60 |
| 51 | Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection. *Retrovirology*, **2011**, 8, 16 | 3.6 | 59 |
| 50 | Evidence for IFN□nduced, SAMHD1-independent inhibitors of early HIV-1 infection. *Retrovirology*, **2013**, 10, 23 | 3.6 | 49 |

| | | | |
|---|---|---|---|
| 49 | Lv2, a novel postentry restriction, is mediated by both capsid and envelope. *Journal of Virology*, **2004**, 78, 2006-16 | 6.6 | 49 |
| 48 | HIV-1 incorporates ABO histo-blood group antigens that sensitize virions to complement-mediated inactivation. *Blood*, **2005**, 105, 4693-9 | 2.2 | 48 |
| 47 | Preservation of tetherin and CD4 counter-activities in circulating Vpu alleles despite extensive sequence variation within HIV-1 infected individuals. *PLoS Pathogens*, **2014**, 10, e1003895 | 7.6 | 44 |
| 46 | Serine Phosphorylation of HIV-1 Vpu and Its Binding to Tetherin Regulates Interaction with Clathrin Adaptors. *PLoS Pathogens*, **2015**, 11, e1005141 | 7.6 | 43 |
| 45 | Retroviral retention activates a Syk-dependent HemITAM in human tetherin. *Cell Host and Microbe*, **2014**, 16, 291-303 | 23.4 | 40 |
| 44 | CpG Dinucleotides Inhibit HIV-1 Replication through Zinc Finger Antiviral Protein (ZAP)-Dependent and -Independent Mechanisms. *Journal of Virology*, **2020**, 94, | 6.6 | 38 |
| 43 | Envelope-targeted retrovirus vectors transduce melanoma xenografts but not spleen or liver. *Molecular Therapy*, **2002**, 5, 269-74 | 11.7 | 33 |
| 42 | Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England. *Journal of Infection*, **2020**, 81, 931-936 | 18.9 | 32 |
| 41 | Separable determinants of subcellular localization and interaction account for the inability of group O HIV-1 Vpu to counteract tetherin. *Journal of Virology*, **2011**, 85, 9737-48 | 6.6 | 32 |
| 40 | Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. *Nature Microbiology*, **2021**, 6, 1433-1442 | 26.6 | 32 |
| 39 | G2/M cell cycle arrest correlates with primate lentiviral Vpr interaction with the SLX4 complex. *Journal of Virology*, **2015**, 89, 230-40 | 6.6 | 31 |
| 38 | An envelope-determined, pH-independent endocytic route of viral entry determines the susceptibility of human immunodeficiency virus type 1 (HIV-1) and HIV-2 to Lv2 restriction. *Journal of Virology*, **2005**, 79, 9410-8 | 6.6 | 31 |
| 37 | Comparative performance of SARS-CoV-2 lateral flow antigen tests and association with detection of infectious virus in clinical specimens: a single-centre laboratory evaluation study. *Lancet Microbe, The*, **2021**, 2, e461-e471 | 22.2 | 31 |
| 36 | Ig-like transcript 7, but not bone marrow stromal cell antigen 2 (also known as HM1.24, tetherin, or CD317), modulates plasmacytoid dendritic cell function in primary human blood leukocytes. *Journal of Immunology*, **2013**, 190, 2622-30 | 5.3 | 30 |
| 35 | Human immunodeficiency virus types 1 and 2 have different replication kinetics in human primary macrophage culture. *Journal of General Virology*, **2006**, 87, 411-418 | 4.9 | 25 |
| 34 | Differential sensitivities of tetherin isoforms to counteraction by primate lentiviruses. *Journal of Virology*, **2014**, 88, 5845-58 | 6.6 | 21 |
| 33 | The Envelope Gene of Transmitted HIV-1 Resists a Late Interferon Gamma-Induced Block. *Journal of Virology*, **2017**, 91, | 6.6 | 20 |
| 32 | Identification of a receptor for an extinct virus. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 19496-501 | 11.5 | 17 |

| | | | |
|---|---|---|---|
| 31 | Inhibiting the Ins and Outs of HIV Replication: Cell-Intrinsic Antiretroviral Restrictions at the Plasma Membrane. *Frontiers in Immunology*, **2017**, 8, 1853 | 8.4 | 15 |
| 30 | Resilient SARS-CoV-2 diagnostics workflows including viral heat inactivation **2021**, | | 15 |
| 29 | Real-world evaluation of a novel technology for quantitative simultaneous antibody detection against multiple SARS-CoV-2 antigens in a cohort of patients presenting with COVID-19 syndrome. *Analyst, The*, **2020**, 145, 5638-5646 | 5 | 14 |
| 28 | HLA-C downregulation by HIV-1 adapts to host HLA genotype. *PLoS Pathogens*, **2018**, 14, e1007257 | 7.6 | 14 |
| 27 | Resilient SARS-CoV-2 diagnostics workflows including viral heat inactivation. *PLoS ONE*, **2021**, 16, e0256813 | 3.7 | 11 |
| 26 | HIV-1 Vpu Downregulates Tim-3 from the Surface of Infected CD4 T Cells. *Journal of Virology*, **2020**, 94, | 6.6 | 10 |
| 25 | Targeted Restriction of Viral Gene Expression and Replication by the ZAP Antiviral System. *Annual Review of Virology*, **2021**, 8, 265-283 | 14.6 | 10 |
| 24 | A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infection. *Scientific Reports*, **2017**, 7, 1057 | 4.9 | 9 |
| 23 | Adeno-associated virus Rep proteins antagonize phosphatase PP1 to counteract KAP1 repression of the latent viral genome. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E3529-E3538 | 11.5 | 8 |
| 22 | Fake Science: XMRV, COVID-19, and the Toxic Legacy of Dr. Judy Mikovits. *AIDS Research and Human Retroviruses*, **2020**, 36, 545-549 | 1.6 | 6 |
| 21 | The sheep tetherin paralog oBST2B blocks envelope glycoprotein incorporation into nascent retroviral virions. *Journal of Virology*, **2015**, 89, 535-44 | 6.6 | 6 |
| 20 | The P681H mutation in the Spike glycoprotein confers Type I interferon resistance in the SARS-CoV-2 alpha (B.1.1.7) variant | | 6 |
| 19 | S-farnesylation is essential for antiviral activity of the long ZAP isoform against RNA viruses with diverse replication strategies. *PLoS Pathogens*, **2021**, 17, e1009726 | 7.6 | 6 |
| 18 | Sensitivity to BST-2 restriction correlates with Orthobunyavirus host range. *Virology*, **2017**, 509, 121-130 | 3.6 | 5 |
| 17 | Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections **2021**, | | 5 |
| 16 | Upregulation of BST-2 by Type I Interferons Reduces the Capacity of Vpu To Protect HIV-1-Infected Cells from NK Cell Responses. *MBio*, **2019**, 10, | 7.8 | 4 |
| 15 | Combined epidemiological and genomic analysis of nosocomial SARS-CoV-2 transmission identifies community social distancing as the dominant intervention reducing outbreaks | | 3 |
| 14 | The polybasic cleavage site in the SARS-CoV-2 spike modulates viral sensitivity to Type I IFN and IFITM2 | | 3 |

| | | | |
|---|---|---|---|
| 13 | Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection syndromes: Results from a pilot service implemented during the first pandemic wave. *PLoS ONE*, **2021**, 16, e0249791 | 3.7 | 3 |
| 12 | More than the Eye Can See: Shedding New Light on SARS-CoV-2 Lateral Flow Device-Based Immunoassays. *ACS Applied Materials & Interfaces*, **2021**, 13, 25694-25700 | 9.5 | 3 |
| 11 | TMPRSS2 promotes SARS-CoV-2 evasion from NCOA7-mediated restriction. *PLoS Pathogens*, **2021**, 17, e1009820 | 7.6 | 2 |
| 10 | KHNYN is essential for ZAP-mediated restriction of HIV-1 containing clustered CpG dinucleotides | | 1 |
| 9 | Translational Research in the Time of COVID-19-Dissolving Boundaries. *PLoS Pathogens*, **2020**, 16, e1008888 | 7.8 | 1 |
| 8 | Disrupted Peyer's Patch Microanatomy in COVID-19 Including Germinal Centre Atrophy Independent of Local Virus.. *Frontiers in Immunology*, **2022**, 13, 838328 | 8.4 | 1 |
| 7 | Homebrew: an economical and sensitive glassmilk-based nucleic-acid extraction method for SARS-CoV-2 diagnostics.. *Cell Reports Methods*, **2022**, 100186 | | 1 |
| 6 | Exercising Restraint. *Cell Host and Microbe*, **2017**, 21, 274-277 | 23.4 | 0 |
| 5 | Homebrew: Protocol for glassmilk-based nucleic-acid extraction for SARS-CoV-2 diagnostics.. *STAR Protocols*, **2022**, 3, 101300 | 1.4 | 0 |
| 4 | TRIM25 and ZAP target the Ebola virus ribonucleoprotein complex to mediate interferon-induced restriction.. *PLoS Pathogens*, **2022**, 18, e1010530 | 7.6 | 0 |
| 3 | SIV envelope acquires a nefarious habit. *Cell Host and Microbe*, **2011**, 9, 3-5 | 23.4 | |
| 2 | Vpu, Tetherin and Innate Immunity: Antiviral Restriction of Retroviral Particle Release **2010**, 271-305 | | |
| 1 | Minimal impact of ZAP on lentiviral vector production and transduction efficiency. *Molecular Therapy - Methods and Clinical Development*, **2021**, 23, 147-157 | 6.4 | |